Global CAR T-Cell Immunotherapy Market by Type (Monotherapy and Combination Therapy), By Application (Hematologic Malignancies and Solid Malignancies) Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2019-2025

Global CAR T-Cell Immunotherapy Market: Overview

Global CAR T-Cell Immunotherapy market is estimated to reach $ 3.21 Billion by 2025. CAR T-cells are a type of adoptive cell therapy or immunotherapy, in which T cells are generally collected from a patient’s blood, re-engineered in a laboratory. After reengineering, the T cells are known as “chimeric antigen receptor (CAR) T cells. When CAR-T cells are injected into patients, they can act as “living drugs” against cancer cells.

Global CAR T-Cell Immunotherapy Market: Growth Factors

Increasing healthcare insurance and expenditure with better healthcare infrastructure, approvals from US Food and Drug Administration for cancer therapies, and growing prevalence and incidence of cancer across the globe are key driving factors of the market. However, less experienced healthcare professionals coupled with lack of awareness about such therapies among population might hamper growth of the market. Increasing technological advancement in various treatment therapies and increasing CAR-T cell research investments by leading players are major factors that create lucrative opportunities for the market in the near future.

Global CAR T-Cell Immunotherapy Market: Segmentation

The global CAR T-Cell Immunotherapy market is mainly classified based on Type, Application. Type is further segmented into Monotherapy and Combination Therapy. By Application, the market is divided into Hematologic Malignancies and Solid Malignancies.

Global CAR T-Cell Immunotherapy Market: Regional Analysis

Based on geography, the global CAR T-Cell Immunotherapy market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

Global CAR T-Cell Immunotherapy Market: Competitive Players

Key players operating in the market include AbbVie Inc., Celgene Corporation, Kite Pharma, Oxford BioMedica, Novartis International AG, Gilead Sciences, Inc., Pfizer, Inc., Cellectis, Bellicum Pharmaceuticals, Inc., Mustang Bio, CARsgen Therapeutics Ltd, Xyphos, Minerva Biotechnologies, Adaptimmune, and Ziopharm Oncology Inc.

CAR T-Cell Immunotherapy Market Key Segments:

By Type

• Monotherapy
• Combination Therapy

By Application

• Hematologic Malignancies
• Solid Malignancies

By Geography

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • U.K
  • Germany
  • France
  • Italy
  • Rest of Europe
• Asia Pacific
  • India
  • China
  • Japan
  • South Korea
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • GCC Countries
  • Egypt
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. CAR T-Cell Immunotherapy Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Increasing healthcare insurance and expenditure with better healthcare infrastructure
3.3.2. Approvals from US food and drug administration for cancer therapies
3.3.3. Growing prevalence and incidence of cancer across the globe
3.4. Restraints
3.4.1. Less experienced healthcare professionals
3.4.2. Lack of awareness about such therapies among the population
3.5. Opportunity
3.5.1. Increasing technological advancement in various treatment therapies
3.5.2. Increasing CAR-T cell research investments by leading players
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Monotherapy
4.2.1. Market Size & Forecast
4.3. Combination Therapy
4.3.1. Market Size & Forecast

5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Hematologic Malignancies
5.2.1. Market Size & Forecast
5.3. Solid Malignancies
5.3.1. Market Size & Forecast

6. CAR T-Cell Immunotherapy Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America CAR T-Cell Immunotherapy Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Application
6.2.4. The U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe CAR T-Cell Immunotherapy Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Application
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific CAR T-Cell Immunotherapy Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Application
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America CAR T-Cell Immunotherapy Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Application
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. The Middle East & Africa CAR T-Cell Immunotherapy Market
6.6.1. The Middle East & Africa Market Size & Forecast, By Country
6.6.2. The Middle East & Africa Market Size & Forecast, By Type
6.6.3. The Middle East & Africa Market Size & Forecast, By Application
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. AbbVie Inc.
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. AbbVie Inc. Product Category, Application, and Specification
7.1.3. AbbVie Inc. Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Celgene Corporation
7.3. Kite Pharma
7.4. Oxford BioMedica
7.5. Novartis International AG
7.6. Gilead Sciences, Inc.
7.7. Pfizer, Inc.
7.8. Cellectis
7.9. Bellicum Pharmaceuticals, Inc.
7.10. Mustang Bio
7.11. CARsgen Therapeutics Ltd
7.12. Xyphos
7.13. Minerva Biotechnologies
7.14. Adaptimmune
7.15. Ziopharm Oncology, Inc.

Key Market Players

• AbbVie Inc.
• Celgene Corporation
• Kite Pharma
• Oxford BioMedica
• Novartis International AG
• Gilead Sciences, Inc.
• Pfizer, Inc.
• Cellectis
• Bellicum Pharmaceuticals, Inc.
• Mustang Bio
• CARsgen Therapeutics Ltd
• Xyphos
• Minerva Biotechnologies
• Adaptimmune
• Ziopharm Oncology, Inc.